Close

Regeneron's (REGN) EYLEA Receives Positive CHMP Opinion for CRVO/BRVO-Related Visual Impairment

January 23, 2015 7:33 AM EST Send to a Friend
Regeneron (NASDAQ: REGN) announced that EYLEA (aflibercept) Injection has been recommended for approval by the European Committee for Medicinal Products ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login